News | February 10, 2024
Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
One in two women with advanced ovarian cancer has an HRD-positive tumor
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)